Letters in Peptide Science,
`ESCOM
`
`| (1994) 197-205
`
`LIPS 026
`
`197
`
`Sequence dependence of aspartimide formation during
`9-fluorenylmethoxycarbony] solid-phase peptide synthesis
`
`Janelle L. Lauer*®, Cynthia G. Fields*® and Gregg B. Fields?**
`“Department of Laboratory Medicine and Pathology, "Biomedical Engineering Center and ‘Department of Biochemistry,
`University of Minnesota, Box 107, Minneapolis, MN 55455, US.A.
`
`Received 31 January 1995
`Accepted 23 February 1995
`
`Key words: Aspartimide; Fmoc solid-phase peptide synthesis; Piperidides; Side reactions
`
`SUMMARY
`
`Wehave examined the sequence dependence of aspartimide formation during Fmoc-based solid-phase synthesis
`of the peptide Val-Lys-Asp-X-Tyr-Ile. The extent of aspartimide formation and subsequent conversion to the a-
`or B-piperidide was characterized and quantitated by analytical reversed-phase high-performanceliquid chromatog-
`raphy and fast atom bombardment mass spectrometry. Aspartimide formation occurred for X = Arg(Pmc),
`Asn(Trt), Asp(OrBu), Cys(Acm), Gly, Ser, Thr and Thr(¢Bu). No single approach was found that could inhibit this
`side reaction for all sequences. The most effective combinations,
`in general, for minimization of aspartimide
`formation were (i) tert-butyl side-chain protection of aspartate, piperidine for removal of the Fmoc group, and
`either 1-hydroxybenzotriazole or 2,4-dinitrophenol as an additive to the piperidine solution; or (ii) l-adamantyl
`side-chain protection of aspartate and 1,8-diazabicyclo[5.4.0]undec-7-ene for removal of the Fmoc group.
`
`INTRODUCTION
`
`Successful solid-phase syntheses are dependent
`upon highly efficient coupling/deprotection cycles
`and minimization of deleterious side reactions.
`The cyclization of aspartate to form aspartimide
`has long been recognized as a substantial side
`reaction occurring during both synthesis and
`storage of peptides [1-3]. Aspartimide formation
`during peptide synthesis can be either acid or base
`catalyzed, with the kinetics of ring closure de-
`pending upon the nature and strength of the acid
`or base, the structure of the aspartate side-chain
`protecting group, and the aspartate carboxyl
`
`
`*To whom correspondence should be addressed.
`
`0929-5666/$ 10.00 © 1995 ESCOM Science Publishers B.V.
`
`neighboring residue. Extensive studies have been
`published of aspartimide formation during tert-
`butyloxycarbonyl (Boc)-based peptide synthesis
`which have focused on protecting group strategies
`[4,5], sequence dependence [6], and the nature and
`strength of the acid or tertiary base [5,7]. These
`studies found that aspartimide formation can be
`adequately suppressed by additives such as 1-
`hydroxybenzotriazole (HOBt) or 2,4-dinitrophenol
`(Dnp) during base neutralization [8] or by using
`2-adamantyl
`(2-Ada) or cyclohexyl side-chain
`protection of aspartate instead of benzyl! (Bzl)
`protection [4,5].
`It had been assumed that
`
`for 9-fluorenyl-
`
`MSNExhibit 1024 - Page 1 of 9
`MSNv. Bausch - IPR2023-00016
`
`

`

`198
`
`methoxycarbonyl (Fmoc)-based solid-phase syn-
`thesis,
`tert-butyl (fBu) side-chain protection of
`aspartate inhibits aspartimide formation. How-
`ever, Nicolas et al. [9] found substantial asparti-
`mide formation (see Scheme 1) resulting from
`piperidine treatment of the resin-bound sequence
`Val-Lys(Boc)-Asp(O7¢Bu)-Gly-Tyr(¢Bu)-Ile. Sub-
`sequently, other sequences have been found to be
`susceptible to aspartimide formation during Fmoc
`solid-phase synthesis [10-13]. As shown in Scheme
`1, aspartimide-containing peptides can be con-
`verted to the o- or B-piperidide by continued
`exposure to piperidine during solid-phase syn-
`thesis [11-14]. Alternatively, aqueous conditions
`could result in ring opening to either the a- or B-
`peptide. Ring opening to either the piperidide or
`
`peptide is accompanied by aspartate racemization
`[15]. Although comprehensive studies have not
`been performed, aspartimide and piperidide for-
`mation have been shown to be dependent upon
`the peptide sequence, solvent polarity, and con-
`formation of the peptide chain [11,13,16,17]. We
`have further examined the sequence dependence
`of aspartimide formation using the model peptide
`Val-Lys-Asp-X-Tyr-Ile, based on the initial stud-
`ies of Nicolas et al.
`[9]. In addition, we have
`compared the effect of different bases [piperidine
`versus 1,8-diazabicyclo[5.4.0]Jundec-7-ene (DBU)},
`additives (HOBt and Dnp), and aspartate side-
`chain protecting groups {tBu and 1-adamanty]l(1-
`Ada)] [4,18] on aspartimide and subsequentpiper-
`idide formation.
`
`0
`
`—-NH—CH-—-C-—NH—_
`-Piperidide
`HC
`B-Piperi
`—Nn_
`)
`|0
`
`|c
`
`+
`
`9 |
`
`TNE—N
`HC
`o-Piperidide
`C—NH—
`
`|me
`
`po
`—nu—cH-—c” Aspartimide
`piperidine
`
`H,C
`N
`™.7 >
`I0
`
`aqueous base
`
`°
`
`1
`-——NH—-CH—C —NH——
`|
`tat
`ioO
`
`a-Peptide
`
`I
`—NH—CH—C—0-
`
`+
`
`B-Peptide
`mf
`jooO
`
`Scheme 1. Formation and ring opening reactions of aspartimide.
`
`MSNExhibit 1024 - Page 2 of 9
`MSNv. Bausch - IPR2023-00016
`
`

`

`METHODS
`
`All standard peptide synthesis chemicals were
`analytical reagent grade or better and purchased
`from Applied Biosystems, Inc. (Foster City, CA)
`or Fisher (Pittsburgh, PA). DBU was obtained
`from Aldrich (Milwaukee, WI),
`trifluoroacetic
`acid (TFA) from Applied Biosystems, benzoic
`anhydride from Kodak, Fmoc-Ile-4-hydroxymeth-
`ylphenoxy (HMP)resin (substitution level = 0.46
`mmol/g) and benzotriazole-1-yl-oxy-tris-pyrrolidi-
`nophosphonium hexafluorophosphate (PyBOP)
`from Novabiochem (La Jolla, CA), 2-(1 4-benzo-
`triazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluo-
`rophosphate (HBTU)from Richelieu Biotechno-
`logies (St.-Hyacinthe, Quebec), and all Fmoc-
`amino acids from Novabiochem or Millipore
`Corp. (Bedford, MA). All amino acids are of the
`L-configuration where applicable.
`Incorporation of individual amino acids was by
`Fmocsolid-phase methodology on either an Ap-
`plied Biosystems 431A peptide synthesizer or a
`Gilson automated multiple peptide synthesizer
`AMS422. Cycles for the ABI 431A were as de-
`scribed [19], while cycles for the Gilson AMS 422
`were modified from those described previously
`[20] by using double couplings with sixfold
`excesses of Fmoc-amino acids. All peptides were
`assembled on Fmoc-Ile-HMP resin, capped with
`a 10-fold excess of benzoic anhydride using stan-
`dard coupling cycles, and cleaved and deprotected
`with H,O-TFA (1:19) as described [21]. Peptides
`were purified by preparative reversed-phase high-
`performance liquid chromatography (RP-HPLC)
`on a Rainin AutoPrep system equipped with a
`Vydac C,, column (15-20 um particle size, 300 A
`pore size, 250 x 22 mm). The elution gradient was
`0-60% B in 60 min at a flow rate of 5.0 ml/min,
`where A was water containing 0.1% TFA and B
`was acetonitrile containing 0.1% TFA. Detection
`was at 229 nm. Analytical RP-HPLC wasper-
`formed on a Hewlett-Packard 1090 Liquid Chro-
`matograph equipped with a Dynamax C,, column
`(5 um particle size, 300 A pore size, 250 x 4.6
`mm). The elution gradient was 0-60% B in 45
`
`199
`
`min at a flow rate of 1.0 ml/min, where A was
`water containing 0.045% TFA and B wasaceto-
`nitrile containing 0.035% TFA. Detection was at
`230 nm. Elution peaks were integrated using the
`Hewlett-Packard ChemStation software set at
`peak width 0.100, threshold —2, and area reject
`<10% of the largest peak.
`Edman degradation sequence analysis was
`performed on an Applied Biosystems 477A pro-
`tein sequencer/120A analyzer and fast atom bom-
`bardment mass spectrometry (FABMS) on a VG
`7070E-HF mass spectrometer as described previ-
`ously [19,22]. Sequence analysis of selected pep-
`tide-resins indicated efficient assemblies. Mass
`spectral analysis of the benzoyl-Val-Lys-Asp-X-
`Tyr-Ile peptides (either purified or crude when no
`side products were seen by analytical RP-HPLC)
`gave (theoretical molecular weights are given in
`parentheses): X = Ala, [M+H]* = 812.4 Da (812.8
`Da); X = aminoisobutyric acid (Aib), [M+H]* =
`826.4 Da (826.9 Da); X = Arg (from Arg(Pmc)),
`[M+H]* = 897.4 Da (897.9 Da); X = Asn (from
`Asn(Trt)), [M+H]’ = 855.4 Da (855.8 Da); X =
`Asp (from Asp(OrBu)), [M+H]* = 856.5 Da (856.8
`Da); X = Cys (from Cys(Trt)), [M+H]* = 844.5 Da
`(844.9 Da); X = Cys(Acm), [M+H]’ = 915.4 Da
`(916.0 Da); X = Gln (from Gln(Trt)), [M+H]* =
`869.5 Da (869.9 Da); X = Glu (from Glu(OrBu)),
`[M+H]* = 870.5 Da (870.9 Da); X = His (from
`His(Trt)), [M+H]* = 878.5 Da (878.9 Da); X = Ile,
`[M+H]* = 854.5 Da (854.9 Da); X = Leu, [M+H]*
`= 854.5 Da (854.9 Da); X = Lys (from Lys(Boc)),
`[M+H}]’ = 869.5 Da (869.9 Da); X = Met, [M+H]*
`= 872.5 Da (873.0 Da); X = Phe, [M+H]* = 888.5
`Da (888.9 Da); X = Pro,
`[M+H]* = 838.5 Da
`(838.9 Da); X = Ser, [M+H]* = 828.5 Da (828.8
`Da); X = Ser (from Ser(#Bu)), [M+H]* = 828.5 Da
`(828.8 Da); X = Thr, [M+H]* = 842.3 Da (842.9
`Da); X = Thr (from Thr(¢Bu)), [M+H]* = 842.5
`Da (842.9 Da); X = Trp,
`[M+H]* = 927.4 Da
`(928.0 Da); X = Trp (from Trp(Boc)), [M+H]* =
`927.5 Da (928.0 Da); X = Tyr (from Tyr(tBu)),
`[M+H]* = 904.6 Da (904.9 Da); and X = Val,
`[M+H]* = 840.5 Da (840.9 Da). FABMSanalysis
`of benzoyl-Val-Lys-Asp-Gly-Tyr-He obtained us-
`
`MSNExhibit 1024 - Page 3 of 9
`MSNv. Bausch - IPR2023-00016
`
`

`

`200
`
`
`19.999
`
`L
`
`nN eo 9g
`
`mAU
`
`9g g
`
`8a
`
`60
`
`428
`
`2a
`
`i]
`
`3.736
`
`5.087
`
`15
`
`25
`2g
`Time (min. )
`
`32
`
`35
`
`Fig. 1. RP-HPLC elution profiles of the cleavage products from (A) peptide-resin 1a after 16 h piperidine treatment; (B) peptide-
`resin Ib after 0 h piperidine treatment; and (C) peptide-resin 1b after 16 h piperidine treatment. The peptides eluting at 18.9 min
`in (A) and 18.8 min in (B) are the desired products ((M+H]* = 798.7 and 798.3 Da). The peptide eluting at 20.0 min is the
`aspartimide-containing product (EM+H]* = 780.3 Da). The peptides eluting at 22.3, 23.7, and 25.1 min are L- or D-, a or B-
`piperidide-containing products ((M+H]* = 865.4 Da).
`
`MSNExhibit 1024 - Page 4 of 9
`MSNv. Bausch - IPR2023-00016
`
`

`

`201
`
`ing Asp(O-1-Ada) gave [M+H]* = 798.5 Da (798.8
`Da).
`
`RESULTS
`
`protected
`side-chain
`of
`conversion
`The
`aspartate to aspartimide can occur by repetitive
`base treatments throughout
`the synthesis of a
`peptide. We chose the sequence Val-Lys-Asp-Gly-
`Tyr-Ile to study aspartimide formation because of
`its susceptibility to base-catalyzed cyclization of
`the aspartate residue during synthesis [9]. Initially,
`to compare the extent of aspartimide formation,
`peptide-resins la and 1b were synthesized, where
`1a contained aspartate with tBu side-chain (p-
`carboxyl) protection and 1b contained aspartate
`with ¢Bu a-carboxyl protection and no side-chain
`
`protection. During assembly of 1a and 1b, Fmoc
`removal for each amino acid utilized a 9 min
`treatment with piperidine and 0.1 M HOBt in
`NMP(1:4). Thus, the aspartate residue was ex-
`posed to the piperidine solution for 27 min. The
`peptide-resins were subsequently treated with
`piperidine-DMF (1:4) for 0, 2, 4, 6 and 16 h,
`after which they were cleaved and side-chain de-
`protected for 1 h, and the products were analyzed
`by RP-HPLC. After 0 h treatment, the cleavage
`product from 1a contained only the desired mate-
`rial, eluting at 18.9 min ((M+H]* = 798.7 Da,
`theoretical 798.8 Da). A 16 h treatmentof 1a re-
`sulted in a product containing 39.3% of the de-
`sired material (elution time = 18.9 min), and sev-
`eral later eluting peptides (Fig. 1A). The peptide
`eluting at 20.0 min corresponded to an aspart-
`
`TABLE|
`SEQUENCE DEPENDENCE FOR PIPERIDINE-CATALYZED ASPARTIMIDE FORMATION OF BENZOYL-Val-
`Lys(Boc)-Asp(Of¢Bu)-X-Tyr(tBu)-[le-HMP RESIN
`
`Xx
`
`Percentage desired product
`t=0h
`t=2h
`
`t=4h
`
`t=6h
`
`t=16h
`
`100
`100
`100
`100
`100
`Ala
`100
`100
`100
`100
`100
`Aib
`82.4
`88.8
`94.2
`92.9
`100
`Arg(Pmc)
`77.2
`100
`100
`100
`100
`Asn(Trt)
`88.5
`96.1
`100
`100
`100
`Asp(OrBu)
`52.6
`88.3
`92.0
`100
`100
`Cys(Acm)
`100
`100
`100
`100
`100*
`Cys(Trt)
`100
`100
`100
`100
`100
`Gln(Trt)
`100
`100
`100
`100
`100
`Glu(OrBu)
`39.3
`ND
`ND
`ND?
`100
`Gly
`100
`100
`100
`100
`100
`His(Trt)
`100
`100
`lle
`100
`100
`100
`100
`100
`Leu
`100
`100
`100
`100
`100
`100
`100
`100
`Lys(Boc)
`100
`100
`Met
`100
`100
`100
`100
`100
`Phe
`100
`100
`100
`100
`100
`Pro
`100
`100
`100
`82.9
`100
`Ser
`32.7
`53.9
`62.7
`100
`100
`100
`100
`100
`Ser(¢Bu)
`62.5
`81.0
`Thr
`12.5
`36.1
`44.4
`67.1
`100
`100
`100
`100
`Thr(tBu)
`100
`100
`100
`100
`100
`Trp
`100
`100
`100
`100
`100
`Trp(Boc)
`100
`100
`100
`100
`100
`Tyr(tBu)
`100
`100
`Val
`
`
`100100 100
`
`* The product contained ~10% of a ¢-butylated peptide with the desired sequence ((M+H]* = 900.6 Da, theoretical 901.0 Da).
`> ND = not determined.
`
`MSNExhibit 1024 - Page 5 of 9
`MSNv. Bausch - IPR2023-00016
`
`

`

`202
`
`imide-containing product based on FABMS
`([M+H]* = 780.3 Da, theoretical 780.8 Da). Pep-
`tides eluting at 22.3, 23.7 and 25.1 min corre-
`sponded to piperidide-containing products based
`on FABMS ({M+H}' = 865.4 Da,theoretical 865.8
`Da). After 0 h treatment, the cleavage product
`from 1b contained 75.3% of the desired material,
`eluting at 18.8 min ((M+HJ* = 798.3 Da, theoreti-
`cal 798.8 Da) and 24.7% of the aspartimide-con-
`taining peptide, eluting at 20.0 min (Fig. 1B).
`Thus, aspartimide formation occurred morerapid-
`ly for the B-Asp peptide compared to the o-Asp
`peptide. After a 16 h treatment only the piperi-
`dide-containing products of 1b were seen, eluting
`at 22.3, 23.7 and 25.1 min (Fig. 1C).
`
`1a_benzoyl-Val-Lys(Boc)-Asp(OtBu)-Gly-Tyr-
`(tBu)-Ile-HMPresin
`
`1b benzoyl-Val-Lys(Boc)-B-Asp(o-OrBu)-Gly-
`Tyr(tBu)-Ile-HMP resin
`
`To examine the sequence dependenceofaspart-
`imide formation, 25 different residues were sub-
`stituted for glycine in the Val-Lys-Asp-Gly-Tyr-Ie
`sequence. During assembly of the 25 peptide-
`resins, the aspartate residue was exposed to piper-
`idine and 0.1 M HOBt in DMF (1:4) for 1.85 h.
`Peptide-resins were subsequently treated with pi-
`peridine-DMF (1:4) for 0, 2, 4, 6 and 16h,after
`which they were cleaved and side-chain depro-
`tected for 1 h, and the products were analyzed by
`RP-HPLC (Table 1). The area of the desired
`
`product peak was compared to those of later
`eluting product peaks corresponding to asparti-
`mide- and piperidide-containing peptides (vide
`supra). With no additional piperidine treatment,
`cyclization of aspartate was seen for the sequence
`containing X = Thr. Additional piperidine treat-
`ment resulted in aspartimide formation for se-
`quences containing X = Arg(Pmc) or Ser after 2
`h, Cys(Acm) after 4h, Asp(OrBu) after 6 h, and
`Asn(Trt) or Thr(¢Bu) after 16 h. The extent of
`aspartimide formation increased very slowly over
`time for X = Arg(Pmc), Asp(OrBu), or Cys(Acm),
`but very rapidly for X = Ser or Thr. For all of
`these aspartimide-forming sequences, the use of
`DBU-piperidine~-DMF(1:1:48) instead of piper-
`idine-DMF(1:4) increased the rate of side reac-
`tion (not shown).
`Inhibition of aspartimide formation was studied
`with HOBt or Dnpas additives to the piperidine
`solution. All sequences from Table 1 that gave as-
`partimide formation were exposed to a 16 h pi-
`peridine-DMF(1:4) treatment in the presence of
`0.1 M potential inhibitor. In most cases, either
`HOBtor Dnpcould inhibit, but not always elim-
`inate, aspartate cyclization (Table 2). For the se-
`quences containing X = Cys(Acm), Thr or Thr-
`(tBu), the use of Dnp as an additive significantly
`increased the yield of desired product from 53 to
`76%, 12 to 55%, and 67 to 100%, respectively.
`The synthesis of la was repeated using Fmoc-
`Asp(O-1-Ada) to evaluate the influence of the
`aspartate side-chain protecting group on asparti-
`mide formation. Treatment of benzoyl-Val-Lys-
`
`TABLE 2
`INHIBITION OF PIPERIDINE-CATALYZED ASPARTIMIDE FORMATION OF BENZOYL-Val-Lys(Boc)-Asp(O/Bu)-
`X-Tyr(tBu)-Ile-HMP RESIN
`
`xX
`
`Percentage desired product following 16 h piperidine treatment
`
`
`No additive
`HOBt
`Dnp
`
`95.2
`85.2
`82.4
`Arg(Pmc)
`81.2
`84.8
`77.2
`Asn(Trt)
`100
`92.5
`88.5
`Asp(O1Bu)
`76.3
`68.6
`52.6
`Cys(Acm)
`41.1
`45.9
`32.7
`Ser
`54.9
`28.0
`12.5
`Thr
`
`Thr(tBu) 100 67.1 100
`
`
`
`MSNExhibit 1024 - Page 6 of 9
`MSNv. Bausch - IPR2023-00016
`
`

`

`TABLE 3
`ASPARTIMIDE FORMATION OF BENZOYL-Val-Lys(Boc)-Asp(O-1-Ada)-Gly-Tyr(#Bu)-Ile-HMP RESIN
`Base
`Additive
`
`203
`
`Percentage desired product
`100
`0
`0
`0
`0
`69.3
`86.9
`100
`83.1
`85.0
`73.3
`11.2
`11.6
`12.4
`
`Piperidine
`Piperidine
`Piperidine
`Piperidine
`Piperidine
`Piperidine
`Piperidine
`DBU
`DBU
`DBU
`DBU
`DBU
`DBU
`DBU
`
`None
`None
`None
`None
`None
`HOBt
`Dnp
`None
`None
`None
`None
`None
`HOBt
`Dnp
`
`Time (h)
`0
`2
`4
`6
`16
`16
`16
`0
`2
`4
`6
`16
`16
`16
`
`(Boc)-Asp(O-1-Ada)-Gly-Tyr(¢Bu)-He-HMPresin
`(1c) with piperidine-DMF(1:4) resulted in higher
`levels of side products than when Asp(OrBu) was
`used for the same sequence. For example, a 16 h
`treatment of Ic yielded none of the desired prod-
`uct (Table 3), whereas 39.3% of the desired prod-
`uct was obtained following identical treatment of
`la. Both HOBt and Dnpwereeffective inhibitors
`of aspartimide formation of 1c (Table 3). Treat-
`ment of le with DBU was far less detrimental
`than piperidine. All time points beyond 0 h re-
`sulted in more desired product following DBU
`treatment
`than piperidine. Additives
`such as
`HOBt or Dnp hadlittle effect on inhibition of
`DBU-catalyzed aspartimide formation (Table 3).
`
`DISCUSSION AND CONCLUSIONS
`
`The formation of aspartimide in aspartate-
`containing peptides has been documented for only
`a few sequences assembled by Fmoc chemistry
`{9-13,16,17,23]. A comprehensive study wasclear-
`ly needed to determine if this side reaction is a
`significant problem during Fmoc_ solid-phase
`chemistry. We utilized the sequence Val-Lys-Asp-
`X-Tyr-Ile as a model for aspartimide formation.
`For X = Gly, there was no detectable conversion
`to aspartimide following peptide assembly, but
`60.7% conversion after an additional 16 h expo-
`
`sure to piperidine-DMF(1:4). Assuminga linear
`relationship, this corresponds to 0.63% conversion
`per 10 min treatment. Nicolas et al.
`[9] and
`Quibell et al. [23] found 0.46 and 0.5% conver-
`sion, respectively, per 10 min piperidine-DMF
`(1:4) treatment of resin-bound, side-chain pro-
`tected Val-Lys-Asp-Gly-Tyr-Ie. Our results with
`respect to sequence dependence show that aspart-
`imide formation occurs for X = Thr > Ser > Arg-
`(Pmc) = Cys(Acm) > Asp(O¢Bu) = Asn(Trt) =
`Thr(tBu), where threonine and serine overwhelm-
`ingly gave the most rapid side-product formation.
`It is somewhat surprising that ring closure occurs
`readily in the presence of a bulky side chain [2]
`such as Arg(Pmc). A prior study of base-catalyzed
`aspartimide formation of Boc-Asp(OBzl)-X-B-
`naphthylamide indicated that conversion was
`most rapid for the residues X = Ser > Thr > Gly
`= Asn = Gln [6]. Thus, results of our study are
`consistent with this prior study. We did not exam-
`ine X = Asn or Gin, as there does not appear to
`be mucheffect of Trt side-chain protection of a
`neighboring asparagine or glutamineon inhibition
`or enhancement of aspartimide formation [17].
`Prior studies of aspartimide formation of Asp-
`(OtBu)-X sequences during Fmoc chemistry found
`significant conversion when X = Gly, Ala, Asn,
`Asn(Trt), Gln, and Gln(Trt) [9-13,16,17]. While
`we did see aspartimide formation for X = Gly and
`
`MSNExhibit 1024 - Page 7 of 9
`MSNv. Bausch - IPR2023-00016
`
`

`

`204
`
`.
`
`Asn(Trt), we did not for X = Ala and Gin(Trt).
`Other researchers have shown that not all Asp-
`(OtBu)-Gly are susceptible to cyclization [24]. -
`These results lend further support to the notion
`that aspartimide formation is both sequence and
`conformation dependent[11,17].
`When DBU wasusedinstead of piperidine, the
`rate of aspartimide formation increased for all
`sequences examined. This is consistent with prior
`results with an Asp(O¢Bu)-Asn(Trt) sequence[10].
`Previously, DBU has been shown to remove the
`Fmoc group more rapidly than piperidine [24].
`Fmoc group removal requires a base to abstract
`the acidic proton at the 9-position of the fluorene
`ring system,
`leading to §-elimination. If DBU
`more rapidly removes this proton than piperidine,
`then the increased rate of aspartimide formation
`may bethe result of the rate of abstraction of the
`NHproton leading to cyclization.
`A sufficient number of aspartimide-susceptible
`sequences have now been identified to warrant the
`development of general methods for inhibiting
`aspartate cyclization during Fmoc solid-phase
`synthesis. We have considered the (i) time of base
`treatment; (ii) use of additives during Fmocre-
`moval; and (ii) protecting group strategy. In-
`creased exposure to piperidine or DBU usually
`results in increased aspartimide and/or piperidide
`formation of susceptible sequences, as found pre-
`viously [12,16]. Obviously, minimizing the length
`of base treatment of susceptible sequenceswill, in
`general, reduce aspartimide formation. Additives
`such as HOBt or Dnp were effective inhibitors
`when Asp(OtBu) or Asp(O-1-Ada) was used in
`combination with piperidine, similar to their ef-
`fects on base-catalyzed aspartimide formation of
`Boc-Asp(OBzl)-Gly-B-naphthylamide
`[8]
`and
`Fmoc-Leu-Thr(tBu)-Glu(O7/Bu)-Asp(O¢Bu)-Asn-
`(Trt)-Val-Lys(Boc)-HMPresin [16,17]. The use of
`HOBtas an additive to piperidine solutions does
`not appear to have a detrimental effect on Fmoc
`removal[11,25]. However, neither HOBt nor Dnp
`was an effective inhibitor of aspartimide forma-
`tion during DBU treatment of the Asp(O-1-Ada)
`sequence studied here.
`
`The Ada group has been reported to suppress
`acid-catalyzed aspartimide formation better than
`the-Bzl and cyclohexyl groups[4,18]. It is believed
`that the relative bulkiness of the Ada group is
`responsible for this inhibitory effect [4]. We found
`that the 1-Ada group was (i) more effective at
`suppressing DBU-catalyzed aspartimide formation
`than the piperidine-catalyzed side reaction; and
`(ii) less effective at suppressing piperidine-cata-
`lyzed aspartimide formation than ‘Bu groupside-
`chain protection of aspartate. Based on Adasteric
`effects alone, result (i) is anticipated. However,
`steric effects do not explainresult (1i). It is possible
`that Ada or ¢Bu provides minimalsteric hindrance
`to piperidine abstraction of the NH proton.
`Other approaches for potential inhibition of
`aspartimide formation can also be considered.
`Since the base-catalyzed reaction requires abstrac-
`tion of the NH proton [2], there should be no
`cyclization when the carboxyl neighbor to as-
`partate is an N-alkyl amino acid. This concept is
`supported by ourresults, showing no aspartimide
`formation for the sequence containing an N-alkyl
`amino acid (X = Pro). In a similar fashion, a
`recent study showed minimization of aspartimide
`formation using the 2-hydroxy-4-methoxybenzyl
`(Hmb) N-protecting group prior to the incorpor-
`ation of an aspartate residue [23]. An alternative
`method for
`inhibiting aspartimide formation
`would thus be solid-phase incorporation of an N-
`alkyl amino acid prior to Fmoc-Asp(O/Bu). Based
`on ourstudy, the most effective combinations for
`minimization of aspartimide formation were (i)
`tBu side-chain protection of aspartate, piperidine
`for removal of the Fmoc group, and either HOBt
`or Dnpas an additive to the piperidine solution;
`or (ii) 1-Ada side-chain protection of aspartate
`and DBUfor removal of the Fmoc group.
`
`ACKNOWLEDGEMENTS
`
`We acknowledge support of this work by the
`NIH (DK 44494 and AR 01929), a McKnight-
`Land Grant Professorship, and the Millipore
`Corporation.
`
`MSN Exhibit 1024 - Page 8 of 9
`MSNv. Bausch - IPR2023-00016
`
`

`

`REFERENCES
`
`Barany, G. and Merrifield, R.B., In Gross, E. and Meien-
`hofer, J. (Eds.) The Peptides, Vol. 2, Academic Press, New
`York, NY, 1979, pp. 1-284.
`Bodanszky, M. and Martinez, J., In Gross, E. and Meien-
`hofer, J. (Eds.) The Peptides, Vol. 5, Academic Press, New
`York, NY, 1983, pp. 111-216.
`Capasso, S., Mazzarella, L., Sica, F, Zagari, A. and
`Salvadori, S., J. Chem. Soc., Chem. Commun., (1992) 919.
`Okada, Y. and Iguchi, S., J. Chem. Soc., Perkin Trans. I,
`(1988) 2129.
`Tam, J.P, Riemen, M.W. and Merrifield, R.B., Pept. Res.,
`1 (1988) 6.
`Bodanszky, M. and Kwei, J.Z., Int. J. Pept. Protein Res.,
`12 (1978) 69.
`and
`J.C., Deshmane, SS.
`Bodanszky, M., Tolle,
`Bodanszky, A., Int. J. Pept. Protein Res., 12 (1978) 57.
`Martinez, J. and Bodanszky, M., Int. J. Pept. Protein Res.,
`12 (1978) 277.
`Nicolas, E., Pedroso, E. and Giralt, E., Tetrahedron Lett.,
`30 (1989) 497.
`Kitas, E.A., Knorr, R., Trzeciak, A. and Bannwarth, W.,
`Helv. Chim. Acta, 74 (1991) 1314.
`Délling, R., Beyermann, M., Haenel, J., Kernchen, F,
`Krause, E., Franke, P., Brudel, M. and Bienert, M., 5.
`Chem. Soc., Chem. Commun., (1994) 853.
`Otto, H., Kaiser, D., Kempter, C. and Jung, G., In Maia,
`H.L.S. (Ed.) Peptides 1994 (Proceedings of the 23rd Euro-
`pean Peptide Symposium), ESCOM, Leiden, 1995, pp.
`246-247.
`
`Yang, Y., Sweeney, W.V., Schneider, K., Thérnqvist, S.,
`Chait, B.T. and Tam, J.P., Tetrahedron Lett., 35 (1994)
`9689.
`
`hand
`
`12
`
`13
`
`205
`
`Schon, I., Colombo, R. and Csehi, A., J. Chem. Soc.,
`Chem. Commun., (1983) 505.
`Schon, I., Szirtes, T., Rill, A., Balogh, G., Vadasz, Z.,
`Seprédi, J., Teplan, I., Chino, N., Kumogaye, K.Y. and
`Sakakibara, S., J. Chem. Soc., Chem. Commun., (1991)
`3213.
`
`Ddélling, R., Beyermann, M., Haenel, J, Kernchen, F,,
`Krause, E., Franke, P., Brudel, M. and Bienert, M., In
`Epton, R. (Ed.) Innovation and Perspectives in Solid
`Phase Synthesis, Mayflower Worldwide, Birmingham,
`1994, pp. 489-492.
`Dolling, R., Beyermann, M., Haenel, J, Kernchen, F.,
`Krause, E., Franke, P., Brudel, M. and Bienert, M., In
`Maia, H.L.S. (Ed.) Peptides 1994 (Proceedings of the 23rd
`European Peptide Symposium), ESCOM, Leiden, 1995,
`pp. 244-245.
`Iguchi, S., Tsuda, Y. and Okada, Y., Chem. Pharm. Bull.,
`37 (1989) 2209.
`Fields, C.G., Lovdahl, C.M., Miles, A.J., Matthias Hagen,
`V.L. and Fields, G.B., Biopolymers, 33 (1993) 1695.
`Gausepohl, H., Boulin, C., Kraft, M. and Frank, R.W.,
`Pept. Res., 5 (1992) 315.
`King, D.S., Fields, C.G. and Fields, G.B., Int.
`Protein Res., 36 (1990) 255.
`Fields, C.G., Van Drisse, V.L. and Fields, G.B., Pept.
`Res., 6 (1993) 39.
`Quibell, M., Owen, D., Packman, L.C. and Johnson, T.,
`J. Chem. Soc., Chem. Commun., (1994) 2343.
`Wade, J.D., Bedford, J. Sheppard, R.C. and Tregear,
`G.W, Pept. Res., 4 (1991) 194.
`Otteson, K.M., Harrison, J.L., Ligutom, A. and Ashcroft,
`P,
`In Poster Presentations at
`the Eleventh American
`Peptide Symposium, Applied Biosystems, Inc., Foster City,
`CA, 1989, pp. 34-38.
`
`J. Pept.
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`MSNExhibit 1024 - Page 9 of 9
`MSNv. Bausch - IPR2023-00016
`
`